Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer (CHEIRON)

• ClinicalTrials.gov Identifier: NCT02453009
• Recruitment Status: Unknown
• First Posted: May 25, 2015
• Last Update Posted: May 25, 2015
• Sponsor: Santa Chiara Hospital
• Information provided by (Responsible Party): Orazio Caffo, Santa Chiara Hospital

Study Description

Brief Summary:

The aim of this study is to verify if the addition of enzalutamide to docetaxel is able to improve the disease control in first line CRPC patients.

Condition or disease	Intervention/treatment	Phase
Prostatic Neoplasms	Drug: Docetaxel; Drug: Prednisone; Drug: Enzalutamide	Phase 2

Detailed Description:

CHEIRON trial is a phase II randomized study comparing docetaxel plus enzalutamide to docetaxel alone as first line for castration resistant prostate cancer.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 232 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: CHemotherapy Plus Enzalutamide In First Line Therapy for Castration Resistant prOstate caNcer
• Study Start Date: October 2014
• Estimated Primary Completion Date: September 2016
• Estimated Study Completion Date: December 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A; Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks plus oral enzalutamide 160 mg daily for 24 weeks	Drug: Docetaxel; Pharmaceutical form:solution Route of administration: intravenous; Drug: Prednisone; Pharmaceutical form:tablet Route of administration: oral; Drug: Enzalutamide; Pharmaceutical form : soft gelatin capsules Route of administration: oral; Other Name: Xtandi
Active Comparator: Arm B; Docetaxel 75 mg/m² intravenously on day 1 every 3 weeks for 8 cycles, plus oral prednisone 10 mg daily for 24 weeks	Drug: Docetaxel; Pharmaceutical form:solution Route of administration: intravenous; Drug: Prednisone; Pharmaceutical form:tablet Route of administration: oral

Outcome Measures

Primary Outcome Measures :

1. Rate of patients without progression (according to guideline of Prostate Cancer Clinical Trials Working Group 2 - PCWG2) [ Time Frame: 6 months after docetaxel first administration ]

Secondary Outcome Measures :

1. Rate of objective response according to RECIST criteria [ Time Frame: 6 months after docetaxel first administration ]
2. Rate of biochemical response according to PCWG2 [ Time Frame: 6 months after docetaxel first administration ]
3. Kaplan-Meier estimates of progression-free survival [ Time Frame: 6 months after docetaxel first administration ]
4. Kaplan-Meier estimates of overall survival [ Time Frame: 6 months after docetaxel first administration ]
5. Kaplan-Meier estimates of biochemical progression-free survival [ Time Frame: 6 months after docetaxel first administration ]
6. Rate of treatment-related mortality [ Time Frame: 6 months after docetaxel first administration ]
7. Rate of toxicity-related protocol withdrawal [ Time Frame: 6 months after docetaxel first administration ]
8. Scales of brief pain inventory (BPI) [ Time Frame: 6 months after docetaxel first administration ]
9. Analgesic score [ Time Frame: 6 months after docetaxel first administration ]
10. Functional scales and items of FACT - P questionnaire [ Time Frame: 6 months after docetaxel first administration ]
11. Type and grade of any adverse reaction to treatment, according to CTC-AE v. 4.03 [ Time Frame: 6 months after docetaxel first administration ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: Male
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Histologically- or cytologically-confirmed prostate adenocarcinoma.
2. Metastatic disease.

3. Progressive disease while receiving hormonal therapy or after surgical castration documented by at least one of the following:

   • Increase in measurable disease (RECIST 1.1) [15], and/or
   • Appearance of new lesions, including those on bone scan consistent with progressive prostate cancer, and/or
   • Rising PSA defined as 2 sequential increases above a previous lowest reference value. Each value must be obtained at least 1 week apart. A PSA value of at least 2 ng/ml is required at study entry.

   • Effective castration (serum testosterone levels ≤0.50 ng/dL) by orchiectomy and/or LHRH agonists or antagonist with or without anti-androgens.

     i. If the patient has been treated with LHRH agonists or antagonist (i.e., without orchiectomy), then this therapy should be continued.

   ii. If patients were either started on complete androgen blockade, or had a PSA response (defined by any reduction in PSA sustained for at least 3 months) after adding an antiandrogen, prior anti-androgen therapy should be stopped before randomization: at least 6 weeks for bicalutamide and nilutamide, and at least 4 weeks for flutamide, megestrol acetate and any other hormonal therapy.

4. More than 18 years.
5. Eastern Cooperative Oncology Group (ECOG) performance status <2 (see Appendix 2).
6. Ability to fill the quality of life questionnaire
7. Patient compliance and geographic proximity that allow adequate follow-up.
8. Presence of signed and dated IRB-approved patient informed consent form prior to enrollment into the study.

Exclusion Criteria:

1. Prior chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed >3 years ago.
2. Prior treatment with abiraterone acetate and/or enzalutamide
3. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Patients may be on biphosphonates prior to study entry.
4. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
5. History of brain metastases, uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease.
6. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma). History of loss of consciousness or transient ischemic attack within 12 months of randomization;
7. Inadequate organ and bone marrow function
8. Contraindications to the use of corticosteroid treatment.
9. Clinically significant cardiovascular disease
10. Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
11. Hypersensitivity reaction to the active pharmaceutical ingredient or any of the capsule components, including Labrasol, butylated hydroxyanisole, and butylated hydroxytoluene;
12. Prior malignancy. Adequately treated basal cell or squamous cell skin or superficial (pTis, pTa, and pT1) bladder cancer are allowed, as well as any other cancer for which chemotherapy has been completed >5 years ago and from which the patient has been disease-free for >5 years.
13. Participation in another clinical trial and any concurrent treatment with any investigational drug within 30 days prior to randomization.
14. Any other condition which in the judgment of the investigator would place the subject at undue risk or interfere with the study.

Contacts and Locations

Contacts

Contact: Orazio Caffo, MD; +390461902478; orazio.caffo@apss.tn.it

Locations

Italy

Santa Chiara Hospital; Recruiting

Trento, Italy, 38122

Contact: Orazio Caffo, MD +390461902478 orazio.caffo@apss.tn.it

Sponsors and Collaborators

Santa Chiara Hospital

Investigators

• Study Chair: Orazio Caffo, MD; Santa Chiara Hospital

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Caffo O, Ortega C, Nole F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, Schepisi G, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonico F, Porta C, Pappagallo G, Aglietta M. Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial. Eur J Cancer. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3.

• Responsible Party: Orazio Caffo, MD, Santa Chiara Hospital
• ClinicalTrials.gov Identifier: NCT02453009
• Other Study ID Numbers: TN-CHEIRON
• First Posted: May 25, 2015
• Last Update Posted: May 25, 2015
• Last Verified: May 2015

Additional relevant MeSH terms:

Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases; Prednisone; Docetaxel; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Molecular Mechanisms of Pharmacological Action; Anti-Inflammatory Agents; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs; Antineoplastic Agents, Hormonal